Ado-Over: FDA Uses Prefix To Get Ahead Of Pull-Down Menu Problem
Executive Summary
The use of computer drop-down menus organized by generic name was identified as a source of medication errors in the clinical program, confusing Kadcyla with unconjugated trastuzumab. The solution of adding a three-letter prefix to Kadcyla’s nonproprietary name also seems to be the fix for biosimilars.
You may also be interested in...
Zarxio’s Placeholder Name Hints FDA Wants Generic Feel To Biosimilar Market
Brand firms win with FDA requiring a unique name for biosimilars, but adding suffix will likely group filgrastim products together rather than separate them.
Zarxio’s Placeholder Name Hints FDA Wants Generic Feel To Biosimilar Market
Brand firms win with FDA requiring a unique name for biosimilars, but adding suffix will likely group filgrastim products together rather than separate them.
FDA’s Prefix Solution On Biologic Names Draws Fire
Agency’s nomenclature decisions on Teva’s tbo-filgrastim, Genentech’s ado-trastuzumab emtansine have only added to confusion among products, representatives from the American Society of Health-System Pharmacists and World Health Organization said.